Olinvacimab

DB16265InvestigationalProtein Based Therapies

Olinvacimab is under investigation in clinical trial NCT03033524 (Trial to Evaluate the Safety of Ttac-0001(tanibirumab) in Recurrent Glioblastoma).

Mechanism
Curator reviewed
Also known as
Fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 · Immunoglobulin g1, anti-(human vascular endothelial growth factor receptor 2) (human monoclonal ttac-0001 heavy chain), disulfide with human monoclonal ttac-0001 light chain, dimer · Tanibirumab
Code names
TTAC-0001

Resolves to

Compound
UNIIVFH55IZ5VICAS2095504-49-5
Targets
P35968KDR

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
381Drug interactionsStructured to mechanism, not free text
Sign in
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
7+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Olinvacimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In